RCMI Coordinating Center (RCMI CC) Header Logo

Connection

James Lillard to Leukemia, Lymphocytic, Chronic, B-Cell

Back to Details
This is a "connection" page, showing publications James Lillard has written about Leukemia, Lymphocytic, Chronic, B-Cell.
James Lillard
Connection Strength
1.198
Leukemia, Lymphocytic, Chronic, B-Cell
  1. Griffen TL, Dammer EB, Dill CD, Carey KM, Young CD, Nunez SK, Ohandjo AQ, Kornblau SM, Lillard JW. Multivariate transcriptome analysis identifies networks and key drivers of chronic lymphocytic leukemia relapse risk and patient survival. BMC Med Genomics. 2021 Jun 29; 14(1):171.
    View in: PubMed
    Score: 0.789
  2. Griffen TL, Hoff FW, Qiu Y, Lillard JW, Ferrajoli A, Thompson P, Toro E, Ruiz K, Burger J, Wierda W, Kornblau SM. Proteomic profiling based classification of CLL provides prognostication for modern therapy and identifies novel therapeutic targets. Blood Cancer J. 2022 03 17; 12(3):43.
    View in: PubMed
    Score: 0.207
  3. van Dijk AD, Griffen TL, Qiu YH, Hoff FW, Toro E, Ruiz K, Ruvolo PP, Lillard JW, de Bont ESJM, Burger JA, Wierda W, Kornblau SM. RPPA-based proteomics recognizes distinct epigenetic signatures in chronic lymphocytic leukemia with clinical consequences. Leukemia. 2022 03; 36(3):712-722.
    View in: PubMed
    Score: 0.201
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
RCMI CC is supported by the National Institute on Minority Health and Health Disparities, National Institutes of Health (NIH), through Grant Number U24MD015970. The contents of this site are solely the responsibility of the authors and do not necessarily represent the official views of the NIH

For technical support please contact support